Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05228834 · ClinicalTrials.gov registry record · Phase 3
Voxelotor Neurocognitive Function Study
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT05228834 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT05228834, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition Module of executive abilities in pediatric participants (8 to \< 18 years) with SCD.
Interventions
- DRUG Placebo
- DRUG Voxelotor Only Product in Oral Dose Form
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-06-24 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05228834
The ClinicalTrials.gov registry entry for NCT05228834 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05228834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05228834 about?
NCT05228834 is a clinical study titled "Voxelotor Neurocognitive Function Study". This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition Module of executive abilities in pediatric participants (8 to \< 18 years...
What is the current status of trial NCT05228834?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2022-06-24. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT05228834?
The interventions under investigation include: Placebo (DRUG), Voxelotor Only Product in Oral Dose Form (DRUG).
Who is sponsoring clinical trial NCT05228834?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.